Design strategies for long-acting anti-HIV pharmaceuticals

Yali Sang; Li Ding; Chunlin Zhuang; Fener Chen

doi:10.1016/j.coph.2020.10.005

Design strategies for long-acting anti-HIV pharmaceuticals

Curr Opin Pharmacol. 2020 Oct:54:158-165. doi: 10.1016/j.coph.2020.10.005. Epub 2020 Nov 8.

Authors

Yali Sang¹, Li Ding², Chunlin Zhuang³, Fener Chen⁴

Affiliations

¹ School of Science, Harbin Institute of Technology (Shenzhen), Shenzhen 518055, China; Green Pharmaceutical Engineering Research Center, Harbin Institute of Technology (Shenzhen), Shenzhen 518055, China.
² Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, Shanghai 200433, China.
³ Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, Shanghai 200433, China. Electronic address: zclnathan@163.com.
⁴ School of Science, Harbin Institute of Technology (Shenzhen), Shenzhen 518055, China; Green Pharmaceutical Engineering Research Center, Harbin Institute of Technology (Shenzhen), Shenzhen 518055, China; Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, Shanghai 200433, China. Electronic address: rfchen@fudan.edu.cn.

PMID: 33176247
DOI: 10.1016/j.coph.2020.10.005

Abstract

Current combination antiretroviral therapy (cART) for human immunodeficiency virus (HIV) is limited by the frequent dosing and unfavorable adherence, and the rapid appearance of resistant mutants. Thus, there is a continuous need to improve and optimize the present therapies. The clinical phase III trials of FLAIR and ATLAS, showed two-drug injectable cabotegravir (CAB) and rilpivirine (RPV) formulation is potent, safe, and tolerable in HIV-infected patients. The recent approval of cabenuva (CAB+RPV) by Health Canada is a milestone in the development of long-term therapies for HIV infection. Broadly neutralizing antibodies (bNAbs) with excellent breath and efficiency against HIV have been investigated as LA antiviral weapons. Several modern modalities capable of sustained drug release for long-term treatment and prevention of HIV infection are also in development, such as implants, vaginal rings, and nanotherapies.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Anti-HIV Agents / administration & dosage*
Delayed-Action Preparations / administration & dosage
Drug Combinations
Drug Design
HIV Infections / drug therapy*
Humans

Substances

Anti-HIV Agents
Delayed-Action Preparations
Drug Combinations